Tiziana Life Sciences Ltd. announced the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. As the Chief Operating Officer, Dr. Davis will be responsible for overseeing Tiziana Life Sciences' day-to-day operations, including research and development, manufacturing, clinical trials, and commercialization efforts.

His extensive experience in the biotechnology industry, coupled with his deep understanding of medical affairs, will be invaluable in advancing the company's pipeline and achieving key milestones. During his tenure as Chief Medical Officer, Dr. Davis played a pivotal role in the continued development and progression of Tiziana Life Sciences' therapeutic programs. His strategic insights and dedication to improving patient outcomes have been instrumental in advancing the companies lead asset foralumab into a phase 2 trial in non-active secondary progressive multiple Dr. Davis has over 15 years of experience in Pharma as Chief Medical Officer or Chief Scientific Officer at Endo Pharmaceuticals, URL, Lupin Pharmaceuticals and Sun Pharmaceuticals. He matriculated to the University of Pennsylvania as an undergraduate.

He received his Pharmacy Degree from Temple University and his Medical Degree from the Medical College of Pennsylvania. Dr. Davis undertook his surgical training at Brown University and his Urology training at Washington Hospital Center. Dr. Davis is married to Dr. Annette Davis and has two children, Emma, and Daniel.